Member Info for Iglu

Timelines:
11th November 2019 it was announced by the company that Tissue Regenix was in potential breach of their Covenants.
14th November 2019 Tissue Regenix announced a revised agreement with MidCap
$5.5m repaid immediately to MidCap
$2m Tranche 1 to remain in place.
$5.5m to be added to Tranche 2 which is now $10.5m ( $5.5m + $5m )
Tranche 3 $2.5m remains in place.
MidCap suspend testing of financial covenants until 30th June 2020
Repayment of the outstanding term loan will begin on 1st July 2020 over 48 months.
Drawdown of these tranches is now subject to MidCap’s discretion and satisfactory recapitalisation of the Company at that time (Cost cutting plan then enforce by trx saving approximately 1m per year). TRX is cash generating, it has IP worth around £40m in a fire-sale. The last placing at around 10p was to fund the takeover of CellRight in America, this cost $30m. If you take time to research a company you will see how lazy some posters can be #agenda #troll !

Cyber attacks happen everyday in some companies. It could have been one or the employees let go, or it could have been external. The company concluded all is well and production is back up. My focus is more on the value in this company. Going back a month some excellent work was carried out on what the company would be worth in a fire-sale. I think the total value was around 4p per share. This offers further security to anyone buying at todays price sub 1p. Shareholders are now challenging the Board for an update on Tranche2 funding. Once confirmed this will allow Tissue Regenix to build much needed clean rooms in the 2nd warehouse and also employ much needed skilled labour so the 3rd shift can be added. We also know that Orthopure XT should launch anytime soon. This is a fantastic product and will add further incremental sales once launched. Anyone looking to invest in a company with spectacular products and growth prospects should seriously consider Tissue Regenix. I expect to see II's buying stock as soon as we cross their MCAP threshold. DYOR

https://twitter.com/johnhar49505586/status/1231232917101326337?s=21

Anyone trying to compare Tissue Regenix to SIRUS or other mining companies don't understand fully the business. TRX have locked down IP with dCELL®. They also have a strong range of FDA approved lines in huge demand. They have ongoing clinical studies and a product about to launch (MDR has delayed this). They are ALREADY earning revenues with break even & moving into profit forecasted by just next year. Loan needed relatively small & already agreed just awaiting tranche 2 release by Midcap. Tissue Regenix is quite unique and with uncertainty around Mining and Oil stocks and huge concern around Corronavirus, TRX offers allot ! There is also a wildcard chance of a cheeky bid from a competitor. With a MCAP of £11m, they spend $30m+ on their last acquisition, so there is 100% value in this company for any competitor looking. This is an exciting share which will move quickly on the right news.

I have a few peeps blocked on this board as they can only find negative things to say about Tissue Regenix. I have attached the following valuation from 2016 below. This is was before TRX purchased CellRight and other NPD had come online. Personally I am upbeat about the business, I guess if you are not, you won't be invested short or long term. GLA genuine investors: Valuation: Sum-of-the-parts valuation of £346m
As a result of US dollar strength , we raise our SOTP DCF valuation from £325m to £346m, or 45.6p/share, using a 12.5% WACC. We value the wound care franchise at £188m, orthopaedics at £101m and the cardiac division at £37m. The current market capitalisation, which is subject to an estimated funding requirement of £15m needed to develop OrthoPure XT and XM in the US, does not reflect the full pipeline potential, which could ultimately be attractive to larger medtech companies.

Tissue Regenix closed period ends on Saturday (1 full month after 22nd Jan Q4 announcements). If there is other news pending, the closed period could be extended. It is likely that Directors at TRX will want to buy at this all time low. Their averages are much higher. So I am expecting a window from Saturday until early March to remain open for directors to buy and also release some exciting news. MIDCAP are also highly likely to continue supporting the business going forward. Gareth Jones has significant financial experience in these negotiations and will want a WIN for the business, so I am expecting a slight tweak in the terms of the loan agreement. With shift 2 now fully in place we can expect Q1 to be the best ever trading month for the business. Now is the time to accelerate recruitment for shift 3 and also progress the kitting out of Warehouse 2. This is truly exciting times for Tissue Regenix, a company that has been tipped to be worth £1.5 billion in years to come.

It would seem a few people are selling TRX to buy into NCYT. If you can trade the share and make $$ profit well done. My strategy has been to add TRX when others sell. Next week we will see if this tactic has worked. NCYT MCAP is currently £100m when TRX is £12m. I can see TRX being over 100m market cap also, its been much higher before, and the company now is in a much better position than back then. 1p a share truly a gift :)) GLA

In June 2019 the Woodford announcements started. Ever since Tissue Regenix has been fire fight with II’s dumping us and Cyber attacks targeting us.
It has been a tough share to hold the last few months, especially when the share dropped back from 1.7p.
This week is a big week for all holders. Gareth made it clear that TRX was in a closed period until 1 month after Q4 results. That ends Next Sunday !

The TRX Twitter group also highlighted this weekend that both Old Woodford (LINK) funds are back up and running. At this stage we have not seen any small pocket selling (like on EVE). Why ? Can we expect a TR1 confirming 100% out, or has Gareth and John been proactively selling the story to the II’s and they see the true value, like we do? The recent RNS painted the vision for all existing and new II’s and wow what a story !!

So for me this week is a big week. I will continue to buy at 1p and build a substantial holding here, aiming for 1%. The journey is just begging. I hope Tissue Regenix can batt off any cheeky offer which might land from the US over the next month or two. This company deserves to blossom from the ugly duckling of AIM to the Swan of the FTSE 250 and with their futuristic technology... anything is possible.
DYOR and whilst you are, I will be buying more !

https://twitter.com/johnhar49505586/status/1226758019201077248?s=21

Tissue Regenix shares now sit within the Schroeder empire. The actual fund is called the SUPP. The Times article seems a little misleading and slightly sloppy journalism if you ask me. The link to the fund is :
https://www.schroders.com/en/sysglobalassets/investment-trusts/publicprivate/documents/kid-gb00bvg1cf25-en-gb-20191219-20191219-v2.pdf

The fund details Product code is GB00BVG1CF25

It is clear the fund is underachieving at the moment and we have yet to read a “non Woodford” influenced report, however there appears to be no rush to sell down holdings and most certainly no fire sale.

Reading the report makes me believe more than even what a fantastic opportunity we have here. I’m even more convinced that Midcap will release tranche 2 and soon. Possibly this report is what was required and waiting for by Midcap hence it being officially RNS’d. For me it makes fantastic reading and shows the true potential this company has. Value Can easily be 8p a share and beyond. Break even not far away...and that’s without the new products & licensing agreements being talked about.

Agree with that chart, this companies share price has been brutally beaten down beyond belief. The Woodford rumors partly to blame....sooner or later this will re-rate upwards big time...it will happen patience is key. This is not the usual AIM bag of rubbish dodgy business, it’s a diamond that just need some polishing.

No investor can ever be sure if a company will receive a hostile bid or not. Many factors will influence the potential predator. The RNS today did act as a clear value for money signpost, however it was truly designed to catch the attention of institutional money, rather than hostile. Arthrex and Arms Medical are both extremely progressive companies based in America, after months of negativity around Tissue Regenix, the pathway of opportunity set out in todays report will regain confidence at the most senior levels. The obsession of a placing over the last week in this chatroom, is misspent energy. Tissue Regenix has a excellent relationship with MIDCAP and I have no doubt Gareth (CEO and Financial Wiz), will have this all sorted by the end of FEB. Why the end of Feb.. well directors will be looking to buy in as soon as the closed period is lifted !

Of course TRX are in a strong position to refinance, maybe with Midcap or maybe with another lender. They will be looking for the best rates and best offer. They are an established business with premises, trained employees and amazing products, It’s not a startup company with just big ideas and nothing else. Trx has had fantastic revenues figures increasing over the years, the benefit of the 2nd shift will now start to kick in for the next set of results and talk of a 3rd shift starting bodes well. New products and the new 10 year facility due for completion mid year will be achieved. The new facility will be brought online, probably the plans and contractors to do this are work already in place. Once funding with the lender they choose is achieved things will move very fast....as will the sp. They only need to refurbish a facility they already own. Yes I agree a placing makes no sense at all now, if it was going to be done it would have been on the last trading update when the sp was 1.70. So for me it’s not happening.

TRX purchased CellRight for well over double the MCAP (Us30 million). The portfolio, plus patents has to be worth a minimum 5p in a fire sale. So the true value of the company in a Takeover would be around double this. I would expect an offer to land around 6p and then negotiated up to between 8p and 10p per share. I think we would all be happy with that for a return and I personally would be delighted to see their technology expedited into the market.
I topped up on the dip. Not worried at all. GLA

https://twitter.com/johnhar49505586/status/1225118199961788422?s=21

8p a share is where this will be heading soon, that’s if a takeover doesn’t happen first. It’s so undervalued due to the Woodford rumors and panic selling. Be patient it will come good

I think the company will be partly or fully bought out. The SP is crazy and will be attracting massive interest. A 50m takeover would be around 5p a share. A bargain

CellRight was purchased in August 2017 for $30m. The integration of their technology and Tissue Regenix continues with very exciting prospects.
Products like OrthoPure XT will revolutionise the way crucially ligaments are treated. True investors will understand the value of SurgiPure and Dermapure and how these technologies offer a life line to women suffering with Transvaginal Mesh (as one example).
Biosurgery, Orthopaedics, Dental, Cardiac - these are all categories Tissue Regenix operate in and in most cases lead the market in technology.

Some might see TRX as a 10-15% trade. Other will see a £200m+ business, currently trading at £14m.

nomlungu..I’ve checked all the rns and done as much research as possible. I certainly don’t see a placing, my reason being the funds needed are not huge compared to the Cellright purchase & also the fact that once the new facility is refurbished and up and running break even and profitability will arrive soon after ( as already predicted possible this year in a previous rns). Parts of the TRX business are already self funding according to the last trading update. I believe the Midcap 2nd tranche will be agreed and accessible very soon and if not with Midcap then another lender. The money will be used to refurbish an already acquired facility with a 10 year lease. After this is completed production will increase dramatically & revenues will rocket, then road ahead will be very rosy indeed. That’s my take.